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Purpose: To report 15 year(range:13-17 years) incidence rate of visual 
loss(blindness and visual impairment (VI)), causes and risk factors for all ages, and 
for those 40 years or above at baseline for participants in Andhra Pradesh Eye 
Disease Study(APEDS). 
Design: Population based cohort study 
Methods: All rural participants were interviewed and underwent a comprehensive 
eye examination. Presenting visual acuity(PVA) was measured using a standard 
logarithm of minimum angle of resolution chart at 3 meters. Unaided, presenting, 
pinhole and best-corrected visual acuity(BCVA) were also recorded. World Health 
Organization(WHO) and United States of America(USA) categories of VI and 
blindness were used for analysis. Incident visual loss was defined as the 
development of, or worsening of visual loss of one or more categories.  
Results: At baseline, 7,771 participants were examined and in APEDS III, 
5,395(69.4%) were re-examined. Using WHO categories, the crude incidence rate of 
any visual loss based on PVA and BCVA were 14.6 and 6.3 per 100 person-years, 
respectively. Using US criteria, the values were 22.6 and 10.6 per 100 person-years, 
respectively. More than 90% of visual loss was due to cataract and uncorrected 
refractive error.  Using WHO categories, significant independent risk factors for the 
incident visual loss were increasing age, female, illiterate, past or current smoker 
and current use of alcohol.  Using the USA definition, additional risk factor was lower 
level of education.  
Conclusions: The high incidence likely reflects poor access to eye care in this 

























Blindness and visual impairment (VI) are major public health problems with a 
significant impact on quality of life1-4, economic productivity, mental health,5,6 safety7-
10 and mortality.11 According to recent global data, 36 million people are blind, and 
217 million have moderate to severe VI.12 Although the overall prevalence of 
blindness fell between 1990 and 2015, the number of people who are blind 
increased by 17.6%, and the number with moderate to severe VI increased by 
35.4%. This increase is attributed to population growth and aging,12 and increasing 
urbanization and life style charges.  
 
Data on the magnitude and causes of blindness and VI are derived from cross 
sectional prevalence surveys and provide useful information for planning services 
and resource allocation to address current gaps. However, to plan for the future 
longitudinal incidence data are required. These studies can also provide more robust 
data on risk factors for eye diseases from which causality can be inferred more 
reliably, and can be used to describe the natural history of the disease. However, 
there are only a limited number of incidence studies, as they entail complex logistics, 
require more complex data analysis and are costly. Most studies have been 
undertaken in high income countries,13-18 with fewer from India19 and other 
regions;20-25 all focussed on adults, and had relatively short follow up with only a few 
with 10 or more years.16-18,26  The studies also differ in relation to inclusion criteria, 
age group, and the definitions of risk factors and of end points. We have previously 
reported the prevalence and causes of blindness and VI from our baseline survey, 
the Andhra Pradesh Eye Disease Study 1 (APEDS I).27,28 In this paper, we report the 
incidence of blindness and VI over a mean of 15 years, stratified by age-group, sex, 
causes and risk factors (APEDS III).  
 
METHODS AND DESIGN 
 
Details of the methods for APEDS I and APEDS III have already been published.29,30 
In brief, APEDS I was conducted between 1996 and 2000, and recruited individuals 
from three rural and one urban cluster in undivided Andhra Pradesh (AP) state (i.e., 
before it was divided into two states) in southern India.30 In APEDS I, 10,293 
participants were examined (2,552 urban and 7,771 rural). Socio-demographic data 
and systemic risk factors were recorded for each individual and all underwent a 
detailed, comprehensive eye examination. Before planning the follow up study, in 
2009-10 a feasibility study (APEDS II) was carried out, to trace participants 
examined in APEDS I.  However, due to rapid urbanization over the past decade, it 
was not possible to trace the urban cluster in Hyderabad.11 Hence, only the three 
rural areas in APEDS I were revisited, i.e. Tanuku (West Godavari district), Mudhol 
(Adilabad district) and Thoodukurthy (Mahabubnagar district). The result of APEDS II 
showed that 5,447 (70.1%) participants were available for follow-up, 1,453 (18.7%) 
had migrated and 871 (11.2%) had died.11APEDS III was carried out between 2012 
and 2016 when  participants from these three rural areas were re-examined using 
the same methodology as in APEDS I.30  The aim of APEDS III was to estimate the 
incidence and risk factors for blindness and VI, including cataract, diabetic 
retinopathy (DR), uncorrected refractive error (URE) and glaucoma in participants 
who were disease free at APEDS I. In this paper we report the incidence, causes 
and risk factors for VI and blindness. 
 
Socio-demographic data were collected from participants at their residence, as 
described earlier.29 For participants aged 30 years and above the following data 
were collected: demographic data, history of ocular and systemic conditions such as 
hypertension and diabetes, risk factors, visual function, information related to 
barriers to the uptake of eye care services, and knowledge about a range of eye 
diseases. For those below 30 years of age, personal details, parent’s education and 
occupation, spectacle use, reading habits, previous eye examination, consanguinity 
between parents, and their economic status in childhood were recorded. After the 
interview participants underwent a detailed eye examination at the base hospital.  
 
The clinical team comprised four ophthalmologists, and an optometrist and vision 
technician (VT). The VTs were trained to examine the anterior and posterior 
segment, to measure visual acuity (VA) and undertake refraction. Height, weight and 
blood pressure were each measured three times using standard methods, and mean 
values were used. Presenting distance VA in each eye and then binocularly were 
measured using a standard, illuminated (at least 200lux) logarithm of minimum angle 
of resolution (logMAR) chart at 3 metres, using participants distance correction, if 
applicable. For participants who were not literate, a logMAR "E" chart was used. 
Unaided and pinhole distance VA were recorded. Near VA was measured at a 
distance of 40 cm using a logMAR near vision chart with near correction, if 
applicable, and unaided. Monocular and binocular near vision were assessed. If the 
individual was using spectacles, the power of the spectacles was measured. 
Retinoscopy was undertaken for those with a presenting distance or near VA of less 
than logMAR 0.0 (6/6) and best corrected VA was measured. Undilated slit lamp 
examination (SL 120 Carl Zeiss Meditec, Inc, Dublin, CA) was performed by the 
ophthalmologist, including intraocular pressure measurement using Goldman 
applanation tonometry (Carl ZeissMeditec, Inc, Dublin, CA), before and after pupil 
dilatation. For participants examined at home, IOP was measured using a Perkins 
tonometer. Gonioscopy was performed on all participants and graded by the 
ophthalmologist following the APEDS I protocol, using NMR-K two mirror lens 
(Ocular Instrument Inc., Bellevue, WA, USA).31 Four-mirror gonioscopy was also 
performed with an indirect gonioscopic lens (Volk Opticals Inc., Mentor, OH, USA). 
After gonioscopy, pupils were dilated with tropicamide 1% and phenylephrine 
hydrochloride 2.5% for lens grading and posterior segment examination unless 
contraindicated (i.e. risk of angle closure or active infection). In eyes at risk of angle 
closure (occludable angles), laser iridotomy was performed and the dilated 
examination was done at a later date. Phenylephrine was not used in participants 
with hypertension or cardiac disease. Dilated eye examination included grading of 
changes in the lens, optic disc and retina (diabetic retinopathy and ARMD) using 
standard grading systems, as described earlier.29 Following dilated examination, 
biometry was undertaken and visual fields were assessed using a Humphrey visual 
field analyser (model 720E, Carl Zeiss Meditec, Inc, Dublin, CA). Stereo-
photographs of the disc, macula and retina were taken using a Zeiss FF 450-plus 
fundus camera with VISUPAC digital image archiving system (Carl Zeiss, Jena, 
Germany). Corneal, anterior segment and lens photographs were taken using a 
Topcon photo-slit lamp camera (Topcon DC 3, Bauer Drive, Oakland, NJ). Cirrus 
high-definition-OCT (Carl Zeiss Meditec, Jena, Germany) was used to measure 
retinal nerve fibre layer thickness, optic nerve head and optic disc cupping.  
 
Categories of visual impairment 
In order to provide comparable data, the World Health Organization (WHO) 
categories of VI and blindness were used as well as the United States of America 
(USA) criteria. Data are presented using presenting and best corrected VA in the 
better eye.32 Using WHO criteria, moderate VI was defined as a VA of less than 6/18 
down to 6/60; severe VI as a VA of less than 6/60 down to 3/60; and blindness as a 
VA of less than 3/60. Using the USA definition, moderate VI was defined as VA of 
less than 6/12 to better than 6/60; and blindness as a VA of equal to or worse than 
6/60.  
 
Definitions of incident visual loss and causes 
In this paper we use the term visual loss to encompass all categories of visual 
impairment and blindness, and used the same definitions of incidence as in other 
studies.14,33 The incidence of “any visual loss” was defined as any category  of visual 
loss at APEDS III among those who were not impaired at baseline. The incidence of 
mild VI also relates to those who were not impaired at baseline. The other definitions 
use a combination of progression of visual loss from baseline of one or more 
categories, and new cases of visual loss. For example, the incidence of moderate VI 
includes those who progressed from mild to moderate VI as well as those who were 
not impaired at baseline. Similarly, the incidence of blindness includes those with 
less severe VI at baseline which had progressed to blindness by APEDS III as well 
as those who were not impaired at baseline.  
 
The causes of any VI were documented for each eye and for the person, as in the 
original APEDS protocol.27 The causes identified by the examining ophthalmologist 
were discussed with the principal investigator (RCK) and other co-investigators to 
reach a consensus. If there was inadequate information to make a decision, the 
participant was re-examined by the principal investigator. If cataract and ARMD were 
both present, and in the clinical judgement of the ophthalmologist cataract surgery 
would not improve the VA, the cause was recorded as ARMD.  Similarly, if index 
myopia was present and the vision improved with refraction, the cause of VI was 
recorded as cataract and not uncorrected refractive error.  
 
Analysis 
Stata 13 was used for statistical analysis (StataCorp, Texas, USA). Participants who 
had VA data recorded at APEDS I and APEDS III were included in the analysis, and 
the age and sex specific incidence rate was calculated using person time at risk. All 
subjects examined and having visual acuity data at APEDS I and APEDS III were 
included in analysis, which also included those who had undergone cataract surgery 
during the follow up period. Logistic regression modelling was used to assess 
associations between risk factors and VI and blindness. All data were analysed for 
all ages, and for participants aged ≥40 years at baseline.  For categorical variables in 
univariable analysis, chi-square test or Fisher’s exact test was used. A two tailed 
value of <0.05 was considered statistically significant. T-tests and one-way ANOVA 
were used to compare continuous variables. Multi-collinearity between variables was 
assessed by looking at the variance inflation factor; and fitness of the model was 
assessed using Hosmer Lemeshow test for goodness of fit.  
 
Ethics 
The study was approved by the Ethics Committees of the L V Prasad Eye Institute 
(LVPEI), Hyderabad, India and the London School of Hygiene & Tropical Medicine 
(LSHTM), London. Written informed consent was obtained from all participants and 
legal guardians gave consent for minors (<18 years of age). 
 
RESULTS 
At baseline, 7,771 participants from the three rural clusters aged 0 to 95 years were 
examined. At follow up (mean 15 years, range 13-17), 5,395 (69.4%) participants 
were re-examined (Figure 1). Reasons for non-response at APEDS III were death 
(1,324, 17.0%), migration (778, 10.0%), declined examination (165, 2.1%), and not 
traceable (109, 1.4%). Among 2,790 participants aged ≥40 years at baseline, 1,470 
(52.7 %) were examined. Reasons for non-response were death (1,106, 39.6%), 
migration (92, 3.3%), declined examination (71, 2.5%), and not traceable (51, 1.8%).  
 
The mean age of participants at baseline was 28 (SD ± 17.5) years (Table 1). 52.9% 
were female and 49.0% had not received any formal education. The majority of 
participants did not have diabetes or hypertension, and most did not smoke or take 
alcohol. Those who had died between APEDS I and APEDS III were significantly 
older (p<0.001), and more likely to be male (p<0.001), uneducated (p<0.001), have 
diabetes (p<0.001) and hypertension (p<0.001), and to smoke (p<0.001) and drink 
alcohol (p<0.001). Those who declined to participate in APEDS III were more likely 
to be female (p=0.002), better educated (p<0.001), a non-smoker (p<0.001) and 
non-alcohol drinker (p<0.001).  
 
Table 1. Baseline Characteristics among Participants and Nonparticipants in 
Andhra Pradesh Eye Disease Study III (APEDS III) 
 
Incidence rate of any visual loss for all ages 
Using WHO categories, the crude incidence rate of any visual loss based on 
presenting VA and best correct VA were 14.6 (95% confidence interval (CI): 13.6-
15.7) and 6.3 (95% CI: 6.1-6.4) per 100 person-years, respectively. Using US 
criteria, the values were 22.6 (95% CI: 22.3-23.0) and 10.6 (95% CI: 10.3–10.8) per 
100 person-years, respectively. The crude and age- and sex-adjusted incidence of 
any visual loss was significantly higher in women than men (p<0.05) for WHO and 
US criteria. The incidence increased with age at baseline (Table 2). Figure 2A and 
2B show the incidence of any visual loss for men and women for different age 
groups, using WHO and US criteria respectively 
 
Table 2: 15-year incidence rate of any visual impairment in APEDS III 
according to World Health Organization (WHO) and United States (US) criteria. 
 
Incidence of sub-categories of incidence for all ages 
Using the sub-categories of incidence, WHO definitions and presenting VA, the 
crude age- and sex-adjusted rates were as follows: moderate VI 13.4 (95% CI: 13.1-
13.6), severe VI 2.1 (95% CI: 2-2.2) and blindness 0.9 per 100 person-years (95% 
CI: 0.9-1.0)(Supplementary table 1). Women had significantly higher crude incidence 
of moderate VI (p=0.02), and severe VI (p=0.001) than men, but for blindness there 
was no significant difference by sex (p=0.5). Using best corrected VA, the age- and 
sex-adjusted the crude incidence rates were: moderate VI, 5.5 (95% CI: 5.3-5.7), 
severe VI 0.5 (95% CI: 0.4-0.6) and blindness 1.0 per 100 person-years (95% CI: 
0.9-1.1) (Supplementary table 2). Women had a significantly higher incidence of 
moderate VI (p=0.02) and severe VI (p=0.01) than men, but for blindness there was 
no significant difference by sex (p=0.7).  
 
Using the USA definitions the findings were similar for the crude and age- and sex-
adjusted incidence rates of moderate VI and blindness using presenting and best-
corrected VA, with similar differences between men and women (Supplementary 
tables 3 and 4).  
 
Incidence rate of visual impairment for participants aged aged ≥40 at baseline 
Using WHO definitions and PVA and BCVA, the incidence rate of any visual loss 
was 38.9 (95% CI: 35.9-41.8) and 19.2 (95% CI: 17.1 - 21.4) per 100 person-years, 
respectively.  The incidence of blindness (VA <20/400) using PVA and BCVA was 
2.6 (95% CI: 1.8 - 3.5) and 2.7 per 100 person-years (95% CI: 1.9 - 3.6), 
respectively. Using the USA definition and PVA and BCVA the incidence of any 
visual loss was 54.9 (95% CI: 51.6 - 58.2) and 32.5 per 100 person-years (95% CI: 
29.9 - 35.2), respectively. The incidence of blindness (VA <=20/200) using PVA and 




Using WHO and USA categories of visual loss, cataract and uncorrected refractive 
error were the commonest causes of incident visual impairment and blindness for all 
ages and for those aged ≥40 years at baseline (Table 3), accounting for more than 
90% of all causes. Cataract was the leading cause of blindness in each group, 
accounting for more than 70% of the blindness. Other, less important causes of 
blindness were retinitis pigmentosa, corneal pathology, glaucoma, ARMD and other 
retinal conditions.  
 
Table 3. Causes of incident visual impairment and blindness by age and 
category of visual loss.  
 
Risk factors 
Using WHO categories, significant independent risk factors for the incidence of any 
visual loss were increasing age and being female, not literate, a past or current 
smokers and a current user of alcohol (Table 4). Increasing age was also an 
independent risk factor for blindness as were hypertension, diabetes and a low BMI 
(less than 18.5) but not sex, smoking or alcohol use. The risk factors for any visual 
loss were similar using the USA definition, with lower level of education as an 
additional risk factor. Current use of alcohol was not significant. For blindness, 
significant risk factors were increasing age, female sex and current use of alcohol.  
 
Table 4: Mulivariable analysis of risk factors using WHO and US categories for 
A. incident visual impairment  B incident blindness  
 
DISCUSSION 
This is the first population-based study to report the incidence of visual loss (VI and 
blindness) in a cohort of all ages.  Differences between incidence rates estimated 
using PVA and BCVA indicate that uncorrected refractive error is a major cause of 
incident VI, as reflected in the causes data. However, comparison with other studies 
is limited as they differ in terms of the age group studied, the level of socio-economic 
development of the countries where the studies were undertaken, ethnicity, follow-up 
time, and different definitions of risk factors and incidence were used. For example, 
most used WHO and USA categories of visual impairment,15,20,22-25  while some used 
one definition, limiting comparability across studies.13,17,18,21  
 
Studies of those aged 40 years or above at baseline which reported the incidence of 
VI and blindness using PVA are shown in Table 5 where all the incidence data have 
been converted to an annual % incidence.14,18,20,21,23-25  Using the WHO categories of 
visual loss, the APEDS III study had the highest annual incidence of VI and the 
second highest incidence of blindness. Using the USA categories, APEDS III had the 
highest incidence of blindness and the second highest incidence of VI. These 
findings need to be seen against the relatively low mean age of participants at 
baseline (54.7 years). As cataract and refractive error were the two most common 
causes of incident visual loss, the higher incidence in APEDS III can be explained by 
low access to eye care services; a higher incidence on account of greater exposure 
to risk factors such as environmental factors (ultraviolet exposure), dietary 
differences as well as genetics, cannot be ruled out.    
 
Table 5: Annual incidence of visual impairment and blindness using 
presenting visual acuity in high, middle and low income countries  
 
As expected, and as in other studies, the incidence of any visual loss increased 
substantially with age (Figures 2A and 2B).13-25 More than 50% of those 50 years 
and above at baseline developed some degree of VI, which reinforces the need for 
eye health programme planning to target the older population.  
 
In studies from high income countries, ARMD is one of the leading causes of incident 
VI,14,15,17,34 but in our study ARMD was a very uncommon cause. This likely reflects 
racial, ethnic and demographic differences between studies, and the high incidence 
of cataract which may have masked the presence of ARMD.  As in other studies, 
cataract was an important cause of incident VI13,18,25 as was uncorrected refractive 
error. In our study cataract and uncorrected refractive error were the major causes of 
any visual loss for all age groups as well as those 40 years and above, and together 
they accounted for nearly 90% of any incident visual loss. The high incidence of 
visual loss due to cataract in our study likely reflects that, in rural areas of India, 
individuals either do not access eye care services, or only do so once they have 
considerable loss of vision. The incidence could also be higher in this rural 
population where agriculture is an important occupation, due to exposure to 
ultraviolet light, a poor diet, episodes of severe dehydrational crises and exposure to 
biomass cooking fuel.35  
 
Some studies, but not all, reported a higher incidence of visual loss in females, as 
we found in our study, 16,25,33.13-15,20,21,23 but some reported a higher incidence in 
males.22,26,36 As the major causes of incident blindness in our study were cataract 
and uncorrected refractive error, the gender difference in incidence likely reflects 
gender differences in access to optical and cataract surgical services, although there 
some evidence that females are at greater risk of cataract than males after taking 
account of age, but the reasons are not clear.37   
 
Lower levels of education were another risk factor in our study, with a clear trend for 
incident visual loss. This association has been reported in cross sectional studies 
and in the Beijing Eye Study, another cohort study.25 Prospective studies provide 
greater evidence of causality than cross sectional studies, and in our study the better 
educated were more likely to have occupations with less exposure to known risk 
factors for cataract, and be more aware of and able to access services for cataract 
surgery and spectacle correction. A history of past and current smoking and current 
alcohol consumption were also associated with incident visual loss. Smoking was 
one of the major risk factor for cataract in APEDS I,38 as has been reported in a large 
number of other studies.39 Smoking raises the cadmium levels in the blood which 
inactivates the superoxide dismutase as well as causes oxidative stress, thus 
affecting the lens and causing cataract. Although the association between alcohol 
consumption and cataract is controversial, the alcohol consumed in rural areas in 
India may contain toxins as it is locally brewed and distilled from molasses, a by-
product of sugarcane.  
 
Using the WHO definition, nearly two-third of blindness and VI was due to cataract 
i.e. an annual incidence of 1.85%. In Andhra Pradesh there are approximately 
190,000 adults per million population who are aged 40 years and above (27%) who 
live in rural areas (70%). With an annual incidence of cataract of 1.85%, this would 
translate to 3,500 new cataract blind or VI per million population in rural areas. This 
is despite a high cataract surgical rate of approximately 6,000 per million population 
per year.  
 
The strengths of this study include the large sample size which was representative of 
all ages at baseline, the long follow up, and the detailed clinical examination. In 
addition, quality control measures implemented during the study minimized errors 
and bias. The response rate amongst those who survived was 80.5% which is high. 
The quality and standards applied were similar to studies conducted in high income 
settings.14,16,17,23 
 
Limitations of the study included non-response bias as those who had died were 
older, those who had migrated were younger, and those who declined not to take 
part were also younger, and more likely to be female, better educated, non-smokers 
and non-consumers of alcohol. In addition, it was not possible to trace participants in 
the urban cluster. Given the variability of the non-response it is difficult to say in 
which non-response bias may have influenced the estimate, but an over-estimate 
cannot be ruled out.  In the risk factor analysis, all the factors were fixed at baseline, 
whereas in real life these factors can vary over time. Another limitation is that the 
definition of visual loss did not include visual field loss, thus underestimating the 
incidence, particularly of glaucoma. However, as most population based studies on 
the incidence of VI refer only to VA measurements, the data in this study can be 
compared with previous studies conducted on other ethnic groups.  
 
In conclusion, the incidence of visual loss in this rural population in Indian was high, 
with cataract and uncorrected refractive error as the main causes. Increasing age, 
female sex, lack of education, smoking and alcohol intake were significant risk 
factors. The findings highlight the need to increase access to eye care and optical 
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Table 1. Baseline Characteristics among Participants and Nonparticipants in Andhra Pradesh Eye Disease Study III (APEDS III) 
Characteristic Participants Nonparticipants 
Alive Deceased 
Age in years, mean 
(SD)* 28.0 (17.5) 23.0 (18.0) 55.2 (16.6) 
Age group n (%)  n (%) n (%) 
0 - 29 2768 (51.3) 703 (66.8) 112 (8.5) 
30 - 39 1157 (21.5) 135 (12.8) 106 (8.0) 
40 - 49 774 (14.4) 94 (8.9) 161 (12.2) 
50 - 59 454 (8.4) 64 (6.1) 269 (20.3) 
60+ 242 (4.5) 56 (5.3) 676 (51.1) 
Sex*       
Women 2853 (52.9) 610 (58.0) 629 (47.5) 
Men 2542 (47.1) 442 (42.0) 695 (52.5) 
Education*       
None 2404 (49.0) 369 (38.9) 873 (66.4) 
Primary (1-5) 1407 (28.7) 314 (33.1) 306 (23.3) 
Secondary (6-10) 883 (18.0) 202 (21.3) 110 (8.4) 
Higher (11+) 217 (4.4) 63 (4.3) 25 (1.9) 
Hypertension*       
No 2696 (73.3) 384 (70.9) 657 (52.6) 
Yes 984 (26.7) 158 (29.2) 592 (47.4) 
Diabetes*       
No 5372 (99.6) 1047 (99.5) 1274 (96.2) 
Yes 23 (0.4) 5 (0.5) 50 (3.8) 
Smoking status*       




































Past 153 (2.8) 15 (1.4) 120 (9.1) 
Current 881 (16.3) 119 (11.3) 486 (36.7) 
Alcohol status*       
Never 4105 (76.1) 873 (83.0) 744 (56.2) 
Past 134 (2.5) 20 (1.9) 141 (10.7) 
Current 1156 (21.4) 159 (15.1) 439 (33.2) 
 
Table 2: 15-year incidence rate of any visual impairment in APEDS III according to World Health Organization (WHO) and United 







Incidence in Men Incidence in Women Total Incidence 
N n % 95% CI N n % 95% CI N n % 95% CI 
Presenting 
(WHO) 
0 - 29 1011 14 1.3 1.2 - 1.5 1083 38 3.4 3.1 - 3.7 2094 52 2.5 2.2-2.6 
30 - 39 496 53 10.4 9.8 - 11.2 623 104 16.7 15.9 - 17.4 1119 157 13.9 13.4 - 14.5 
40 - 49 309 94 30.3 28.9 - 31.6 366 126 34.6 33.3 - 35.9 675 220 32.6 31.7 - 33.5 
50 - 59 154 66 42.9 40.9 - 45.0 149 71 47.9 45.7 - 49.9 303 137 45.4 43.9 - 46.8 
60+ 51 31 42.6 39.1 - 46.3 52 32 61.1 57.5 - 64.5 103 63 60.5 58.0 - 62.9 
Crude overall* 2021 258 12.6 12.3 - 13.0 2273 371 16.3 15.9 - 16.7 4294 629 14.6 13.6 - 15.7 
Age & sex 




<30 1027 3 0.3 0.2 - 0.4 1103 3 0.3 0.2 - 0.4 2130 6 0.3 0.2 - 0.3 
30 - 39 500 5 0.9 0.7 - 1.1 640 25 4.1 3.7 - 4.5 1140 30 2.5 2.2 - 2.7 
40 - 49 336 23 6.4 5.8 - 7.1 412 50 12.0 11.2 - 12.9 748 73 9.6 9.1 - 10.2 
50 - 59 194 47 24.1 22.6 - 25.7 213 66 30.4 28.8 - 32.0 407 113 28.0 26.9 - 29.2 
60+ 84 28 33.1 30.6 - 35.9 93 42 45.3 42.6 - 47.9 177 70 39.4 37.6 - 41.3 
Crude overall* 2141 106 4.8 4.6 - 5.1 2461 186 7.6 7.3 - 7.9 4602 292 6.3 6.1 - 6.4 
Age & sex 
adjusted* 2141 135 6.3 5.3 - 7.4 2461 224 9.1 7.8 - 10.3 4602 359 7.8 7.0 - 8.6 
Presenting 
(US) 
0 - 29 998 29 2.8 2.6 - 3.1 1068 91 8.5 8.1 - 8.9 2066 120 5.8 5.1 - 5.6 
30 - 39 479 115 24.2 23.2 - 25.2 593 178 30.7 29.8 - 31.7 1072 293 27.8 27.1 - 28.5 
40 - 49 283 125 44.9 43.4 - 46.4 313 165 53.1 51.7 - 54.6 596 290 49.1 48.1 - 50.2 
50 - 59 123 76 62.2 60.0 - 64.5 119 78 65.5 63.2 - 67.7 242 154 63.8 62.2 - 65.4 
60+ 39 29 73.6 69.8 - 77.1 28 24 85.2 81.5 - 88.6 67 53 78.4 75.7 - 81.0 
Crude overall* 1922 374 19.6 19.2 - 20.1 2121 536 25.4 24.9 - 25.9 4043 910 22.6 22.3 - 23.0 
Age & sex 
adjusted* 1922 430 22.4 20.5 - 24.3 2121 631 29.8 27.8 - 31.7 4043 
105
4 26.1 24.7 - 27.5 




30 - 39 499 21 4.2 3.7 - 4.6 637 40 6.1 5.6 - 6.5 1136 61 5.2 4.9 - 5.6 
40 - 49 331 59 17.8 16.7 - 18.9 402 98 24.5 23.5 - 25.7 733 157 21.5 20.7 - 22.3 
50 - 59 182 69 38.3 36.5 - 40.2 189 90 48.3 46.4 - 50.2 371 159 43.4 42.1 - 44.8 
60+ 67 43 63.6 60.5 - 66.6 70 44 62.8 59.8 - 65.8 137 87 63.2 61.1 - 65.3 
Crude overall* 2105 198 9.4 9.1 - 9.7 2397 279 11.6 11.3 - 11.9 4502 477 10.6 10.3 - 10.8 
Age & sex 
adjusted* 2105 253 12.0 10.7 - 13.5 2397 350 14.6 13.2 - 16.1 4502 602 13.4 12.4 - 14.4 
N = number at risk at baseline; n = incident cases; PVA = presenting visual acuity; VI = Visual Impairment; % (95% CI) = incidence and 95% confidence interval. 
United States criteria. Incidence of any presenting VI is measured as PVA at baseline of 20/40 or better with follow up PVA worse than 20/40. Incidence of best-corrected VI is measured as baseline BCVA 
of 20/40 or better with follow-up BCVA worse than 20/40. 
World Health Organization Criteria. Incidence of any presenting VI is measured as PVA at baseline of 20/60 or better with follow up PVA worse than 20/60. Incidence of best corrected VI is measured as 
baseline BCVA of 20/60 or better with follow-up BCVA worse than 20/60. 
* P value < 0.05. 







Table 3. Causes of incident visual impairment and blindness by age and category of 
visual loss.  
 





All age groups at baseline N (%) N (%) N (%) N (%) 
Cataract 392 (62.3) 27 (62.8) 394 (43.3) 108 (76.1) 
Uncorrected refractive error 187 (29.7) 0 (0) 473 (52.0) 2 (1.4) 
Retinitis pigmentosa 1 (0.2) 5 (11.6) 1 (0.1) 3 (2.1) 
Corneal pathology 8 (1.3) 3 (7) 6 (0.7) 8 (5.6) 
Aged ≥40 years at baseline     
Cataract 308 (73.3) 26 (70.3) 299 (60.2) 92 (76.7) 
Uncorrected refractive error 77 (18.3) 0 (0) 171 (34.4) 1 (0.8) 
Corneal pathology 5 (1.2) 2 (5.4) 2 (0.4) 7 (5.8) 
Retinitis pigmentosa 1 (0.2) 2 (5.4) 1 (0.2) 1 (0.8) 
Glaucoma 4 (1) 2 (5.4) 2 (0.4) 3 (2.5) 
Age related macular 
degeneration 
4 (1) 2 (5.4) 2 (0.4) 3 (2.5) 






























Table 4: Mulivariable analysis of risk factors using WHO and US categories for A. 
incident visual impairment  B incident blindness  
 
A A  B B  
WHO 





Odds ratio (95% CI) 
Age group     
<40 years Reference Reference Reference Reference 
40-49 years 3 (2.4 - 3.8) 2.6 (2.1 - 3.2) 2 (0.6 - 7.2) 
2.4 (1.3 - 
4.4) 
50-59 years 
5.1 (3.8 - 
6.9) 5.1 (3.7 - 7.0) 
5.4 (1.6 - 
17.6) 
7.0 (3.9 - 
12.6) 
>=60 years 
9.3 (5.9 - 
14.7) 9.4 (5.1 - 17.4) 
22.2 (7.2 - 
68.3) 
13.6 (7.4 - 
25) 
Gender         
Male Reference Reference Reference Reference 
Female 
1.8 (1.2 - 
2.5) 1.5 (1.1 - 2.0) 1.7 (0.6 - 4.7) 
2.4 (1.2 - 
4.5) 
Education         
Class 11 and 
above 
Reference Reference Reference Reference 
Class 6 to 10 
1.0 (0.4 - 
2.2) 
1.9  (0.96 - 
3.8) 0.4 (0.3 - 5.0) 
0.6 (0.3 - 
1.5) 
Class 1 to 5 2 (0.9 - 4.3) 3.2 (1.6 - 6.3) 1 (0.1 - 8.4) 1 (0.6-1.7) 
Uneducated 
2.5 (1.2 - 
5.4) 3.8 (1.9 - 7.4) 0.5 (.1 - 4.6)  
Hypertension         
No Reference Reference Reference Reference 
Yes 
1.2 (0.95 - 
1.5) 1.1 (0.9 - 1.4) 2.1 (1.1 - 4.4) 
1.4 (0.9 - 
2.0) 
Diabetes         
No Reference Reference Reference Reference 
Yes 
0.7 (0.2 - 
2.2) 1.7 (0.5 - 5.6) 4.7 (1.1 - 20) 
2.5 (0.6 - 
9.5) 
Body mass 
index         
18.5-24.99 Reference Reference Reference Reference 
<18.5 
1.2 (0.9 - 
1.5) 1.1 (0.9 - 1.4) 2.3 (1.1 - 4.8) 
1.4 (0.9 - 
2.0) 
 25-29.9 
0.9 (0.6 - 
1.4) 1.0 (0.7 - 1.6) 0.9 (0.2 - 3.2) 
0.9 (0.4 - 
1.9) 
 >30 
0.6 (0.2 - 
1.5) 0.4 (0.2 - 1.0)   
1.1 (0.3 - 
5.0) 
Smoking         
Never smoker Reference Reference Reference Reference 
Past smoker 
1.9 (1.1 - 
3.3) 1.8 (1.1 - 3.1) 1.1 (0.3 - 4.5) 
1.1 (0.4 - 
2.8) 
Current smoker 
1.5 (1.1 - 
2.3) 1.4 (1.0 - 1.9) 1.4 (0.5 - 3.9) 
1.1 (0.6 - 
2.2) 
Alcohol 
consumption         
Never  Reference Reference Reference Reference 
Past  
1.1 (0.6 - 
1.9) 0.8 (0.4 - 1.3) 1.6 (0.4 - 6.3) 
1.7 (0.8 - 
4.0) 
Current  
1.5 (1.2 - 
1.9) 1.1 (0.9 - 1.4) 0.9 (0.4 - 2.0) 
1.7 (1.1 - 
2.6) 
Hosmer 
Lemeshow test 0.18 0.72 0.37 0.13 
Table 5: Annual incidence of visual impairment and blindness using presenting 


















































54.7 (40)  4 6357 (73%) 
WHO 0.45 0.05 





2001 55.3 (40)  5 4439 (73%) 
WHO 0.28 0.02 





2003 63.4 (50)  5 1405 (88%) 
WHO 2.48 0.06 








62.5 (50)  6 4414 (49%) 
WHO 1.98 0.25 



















54.7 (40)  15 2790 (53%) 
WHO 2.59 0.17 
USA 3.66 0.56 














    
 

















Supplementary table 1: 15-Year incidence rate of presenting visual impairment and blindness in Andhra Pradesh Eye Disease Study cohort 




  Incidence in Men Incidence in Women Total Incidence 
  N N % 95% CI N n % 95% CI N n % 95% CI 
Moderate 
Age at baseline 
(years)                         
0 - 29 1011 14 1.3 1.2 - 1.5 1081 36 3.2 3.0 - 3.5 2092 50 2.3 2.2 - 2.5 
30 - 39 493 50 10.0 9.3 - 10.7 614 95 15.6 14.8 - 16.3 1107 145 13.1 12.6 - 13.6 
40 - 49 306 91 29.7 28.4 - 31.1 350 110 31.6 30.4 - 32.9 656 201 30.7 29.8 - 31.6 
50 - 59 148 60 40.6 38.5 - 42.7 137 59 43.2 41.0 - 45.4 285 119 41.8 40.4 - 43.4 
60+ 49 29 58.0 54.3 - 61.9 45 25 54.3 50.4 - 58.1 94 54 56.2 53.5 - 58.8 
Crude overall* 2007 244 12.0 11.7 - 12.4 2227 325 14.5 14.2 - 14.9 4234 569 13.4 13.1 - 13.6 








Age at baseline 
(years)                         
0 - 29 1027 1 0.1 0.05 - 0.1 1105 2 0.2 0.1 - 0.3 2132 3 0.1 0.01 - 0.2 
30 - 39 501 2 0.3 0.2 - 0.5 642 12 1.7 1.5 - 2.0 1143 14 1.1 1.0 - 1.3 
40 - 49 343 8 2.1 1.8 - 2.6 414 17 3.9 3.4 - 4.4 757 25 3.1 2.8 - 3.4 
50 - 59 205 13 6.0 5.2 - 6.9 228 24 11.0 10.0 - 12.1 433 37 8.6 8.0 - 9.3 
60+ 97 6 6.2 5.0 - 7.5 107 15 14.5 12.8 - 16.3 204 21 10.6 9.5 - 11.7 
Crude overall* 2173 30 1.3 1.2 - 1.4 2496 70 2.8 2.6 - 3.0 4669 100 2.1 2.0 - 2.2 








Age at baseline 
(years)                         
0 - 29 1029 1 0.1 0.05 - 1.5 1106 1 0.1 0.05 - 0.2 2135 2 0.1 0.05 - 0.1 
30 - 39 505 3 0.6 0.4 - 0.8 643 1 0.2 0.1 - 0.3 1148 4 0.4 0.3 - 0.5 
40 - 49 345 1 0.3 0.1 - 0.5 423 5 1.3 1.0 - 1.6 768 6 0.9 0.7 - 1.0 
50 - 59 210 5 2.5 2.0 - 3.2 236 5 2.1 1.6 - 2.6 446 10 2.3 2.0 - 2.7 
60+ 107 8 7.6 6.3 - 9.0 125 13 10.8 9.4 - 12.3 232 21 9.3 8.4 - 10.3 
Crude overall 2196 18 0.8 0.7 - 0.9 2533 25 1.0 0.9 - 1.1 4729 43 0.9 0.9 -1.0 
Age & sex adjusted 2196 23 1.1 0.7 - 1.6 2533 37 1.5 1.0 - 2.0 4729 60 1.3 1.0 - 1.6 
N = number at risk at baseline; n = incident cases; PVA = presenting binocular visual acuity; % (95% CI) = incidence and 95% confidence interval. 
World Health Organization criteria. Incidence of moderate visual impairment: persons with baseline PVA of 20/60 or better with follow-up PVA worse than 20/60 but better than or equal to 20/200 (not including 
20/60). Severe visual impairment: persons with baseline PVA of better than or equal to 20/200 with follow-up PVA worse than 20/200 but better than or equal to 20/400 (not including 20/200). Incidence of 
blindness: persons with baseline PVA better than or equal to 20/400 but follow-up PVA worse than 20/400 (not including 20/400). 
*P value < 0.05 
Age and sex standardized to the undivided Andhra Pradesh state population 
 
Supplementary table 2: 15-Year incidence rate of best-corrected visual impairment and blindness in Andhra Pradesh Eye Disease 




  Incidence in Men Incidence in Women Total Incidence 
  N n % 95% CI N n % 95% CI N n % 95% CI 
Moderate 
Age at baseline 
(years)                         
0 - 29 1026 2 0·2 0·1 - 0·3 1102 2 0·2 0·1 - 0·3 2128 4 0·2 0·1 - 0·2 
30 - 39 499 4 0·7 0·5 - 0·9 640 25 3·7 3·3 - 4·0 1139 29 2·4 2·2 - 2·6 
40 - 49 335 22 6·2 5·5 - 6·8 405 43 10·7 9·9 - 11·4 740 65 8·6 8·1 - 9·1 
50 - 59 190 43 22·4 20·9 - 24·0 206 59 29·2 27·6 - 30·9 396 102 26·0 
24·9 - 
27·1 
60+ 80 24 30·0 27·3 - 32·6 82 31 37·1 34·4 - 39·9 162 55 33·6 
31·7 - 
35·5 
Crude overall* 2130 95 4·4 4·1 - 4·5 2435 160 6·5 6·3 - 6·8 4565 255 5·5 5·3 - 5·7 
Age & sex 
adjusted* 2130 
11
8 5·6 4·6 - 6·6 2435 200 8·2 7·2 - 9·4 4565 316 6·9 6·2 - 7·7 
Severe 
0 - 29 1028 0 0·0 NA 1105 1 0·1 0·04 - 0·1 2133 1 0·04 
0·02 - 
0·06 
30 - 39 503 0 0·0 NA 643 0 0·0 NA 1146 0 0·0 NA 
40 - 49 344 2 0·5 0·3 - 0·7 420 4 0·9 0·7 - 1·2 764 6 0·8 0·6 - 0·9 
50 - 59 206 1 0·5 0·3 - 0·8 233 7 3·2 2·6 - 3·8 439 8 1·9 1·6 - 2·3 
60+ 100 2 1·9 1·3 - 2·7 117 6 5·6 4·6 - 6·8 217 8 3·9 3·3 - 4·6 
Crude overall* 2181 5 0·2 0·1 - 0·3 2518 18 0·7 0·6 - 0·8 4699 23 0·5 0·4 - 0·6 
Age & sex 
adjusted* 2181 2 0·1 0·1 - 0·6 2518 24 0·9 0·6 - 1·4 4699 30 0·6 0·5 - 6·6 
Blindnes
s 
Age at baseline 
(years)                         
0 - 29 1029 1 0·1 0·04 - 0·1 1106 1 0·1 0·05 - 0·1 2135 2 0·1 
0·005 - 
0·1 
30 - 39 506 3 0·6 0·4 - 0·8 644 1 0·2 0·1 - 0·3 1150 4 0·4 0·3 - 0·5 
40 - 49 347 3 0·9 0·7 - 1·2 424 4 1·0 0·8 - 1·3 771 7 1·0 0·8 - 1·2 
50 - 59 211 5 2·5 2·0 - 3·1 240 6 2·5 2·0 - 3·1 451 11 2·5 2·2 - 2·9 
60+ 107 7 6·5 5·3 - 7·8 131 14 11·1 9·7 - 12·5  238 21 9·0 8·1 - 10·0 
Crude overall 2200 19 0·9 0·7 - 10·0 2545 26 1·1 1·0 - 1·2 4745 45 1·0 0·9 - 1·1 
Age & sex adjusted 2200 23 1·0 0·7 - 1·6 2545 38 1·5 1·1 - 2·0 4745 61 1·3 1·0 - 1·6 
N = number at risk at baseline; n = incident cases; BCVA = presenting binocular best corrected visual acuity; % (95% CI) = incidence and 95% confidence interval; NA = no incident cases. 
World Health Organization criteria· Incidence of moderate visual impairment: persons with baseline BCVA of 20/60 or better with follow-up BCVA worse than 20/60 but better than or equal to 
20/200 (not including 20/60). Severe visual impairment: persons with baseline BCVA of better than or equal to 20/200 with follow-up BCVA worse than 20/200 but better than or equal to 20/400 
(not including 20/200). Incidence of blindness: persons with baseline BCVA better than or equal to 20/400 but follow-up BCVA worse than 20/400 (not including 20/400). 
* P value < 0·05 
Age and sex standardized to the undivided Andhra Pradesh state population 
 
Supplementary table 3: 15-Year incidence rate of presenting visual impairment and blindness in Andhra Pradesh Eye Disease 
Study cohort according to United States criteria 
Visual 
Impairment 
  Incidence in Men Incidence in Women Total Incidence 
  N n % 95% CI N n % 95% CI N n % 95% CI 
Moderate 
Age at baseline 
(years)                       
0 - 29 998 29 2·8 2·6 - 3·1 1066 89 8·3 7·9 - 8·8 2064 118 5·7 5·4 - 5·9 
30 - 39 477 113 24·0 22·9 - 24·9 585 170 29·9 28·9 - 30·8 1062 283 27·2 26·5 - 27·9 
40 - 49 281 123 44·6 43·1 - 46·1 301 153 51·2 49·8 - 52·7 582 276 48·0 46·9 - 49·0 
50 - 59 118 71 60·6 58·3 - 62·9 111 70 62·9 60·5 - 65·3 229 141 61·7 60·0 - 63·4 
60+ 38 28 72·8 68-9 - 76·4 24 20 82·7 78·2 - 86·5 62 48 76·5 73·6 – 79.3 
Crude 
overall* 1912 364 19·2 18·8 - 19·7 2087 502 24·1 23·7 - 24·7 3999 866 21·8 21·5 - 22·1 
Age & sex 
adjusted* 1912 422 22·1 20·2 - 24·0 2087 602 28·9 26·9 - 30·8 3999 1018 25·5 24·1 - 26·8 
Blindness 
Age at baseline 
(years)                       
0 - 29 1028 2 0·2 0·1 - 0·2 1105 2 0·2 0·1 - 0·3 2133 4 0·2 0·1 - 0·2 
30 - 39 503 4 0·7 0·5 - 0·9 643 14 2·0 1·8 - 2·3 1146 18 1·5 1·3 - 1·7 
40 - 49 343 8 2·1 1·8 - 2·6 419 22 5·1 4·6 - 5·8 762 30 3·8 3·5 - 4·2 
50 - 59 210 18 8·4 7·4 - 9·4 232 29 12·8 11·7 - 14·0 442 47 10·7 10·0 - 11·5 
60+ 103 13 12·7 11·1 - 14·5 119 30 25·9 23·8 - 27·9 222 43 19·8 18·4 - 21·2 
Crude 
overall* 2187 45 2·0 1·8 - 2·1 2518 97 3·9 3·7 - 4·0 4705 142 30 28·5 - 31·0 
Age & sex 
adjusted* 2187 51 2·3 1·7 - 3·1 2518 118 4·7 3·9 - 5·6 4705 168 3·6 3·1 - 4·1 
N = number at risk at baseline; n = incident cases; PVA = presenting binocular visual acuity; 95% CI = 95% confidence interval 
United States criteria· Incidence of moderate visual impairment: persons with baseline PVA of 20/40 or better with follow-up PVA worse than 20/40 but better than 20/200 (not including 20/40 or 
20/200). Incidence of blindness: persons with baseline PVA better than 20/200 but follow-up PVA 20/200 or worse (including 20/200). 
* P value < 0·001 
Age and sex standardized to the undivided Andhra Pradesh state population 
 
Supplementary table 4: 15-Year incidence rate of best-corrected visual impairment and blindness in Andhra Pradesh Eye Disease 
Study cohort according to United States criteria 
Visual 
Impairment 
  Incidence in Men Incidence in Women Total Incidence 
  N n % 95% CI N n % 95% CI N n % 95% CI 
Moderate 
Age at baseline 
(years)                         
0 - 29 1025 5 0·5 0·4 - 0·6 1098 6 0·5 0·4 - 0·6 2123 11 0·5 0·4 - 0·6 
30 - 39 498 20 4·0 3·6 - 4·5 637 40 6·0 5·6 - 6·5 1135 60 5·1 4·8 - 5·5 
40 - 49 330 58 17·6 16·5 - 18·7 396 92 23·3 22·2 - 24·4 726 150 20·7 20·0 - 21·4 
50 - 59 179 66 37·2 35·3 - 39·1 181 82 46·0 44·1 - 47·9 360 148 41·6 40·3 - 43·0 
60+ 65 41 62·6 59·5 - 65·7 64 38 58·9 55·7 - 62·0 129 79 60·8 58·5 - 63·0 
Crude overall* 2097 190 9·0 8·7 - 9·4 2376 258 10·8 10·4 - 11·1 4473 448 10·0 9·7 - 10·2 
Age & sex 
adjusted* 2097 246 11·7 10·4 - 13·2 2376 329 13·9 12·5 - 15·3 4473 575 12·9 11·9 - 13·9 
Blindness 
Age at baseline 
(years)                         
0 - 29 1029 1 0·1 0·004 - 0·1 1106 2 0·2 0·1 - 0·2 2135 3 0·1 0·09 - 0·1 
30 - 39 505 2 0·4 0·2 - 0·5 644 1 0·2 0·1 - 0·3 1149 3 0·3 0·2 - 0·3 
40 - 49 346 4 1·1 0·8 - 1·3 423 9 2·2 1·9 - 2·6 769 13 1·7 1·5 - 1·9 
50 - 59 211 6 3·0 2·4 - 3·7 238 13 5·6 4·9 - 6·4 449 19 4·4 3·9 - 4·9 
60+ 107 9 8·8 7·0 - 9·7 129 18 14·7 13·2 - 16·4 236 27 11·8 10·8 - 12·9 
Crude overall* 2198 22 1·0 0·9 - 1·1 2540 43 1·8 1·6 - 1·9 4738 65 1·4 1·3 - 1·5 
Age & sex 
adjusted* 2198 28 1·3 0·9 - 1·8 2540 58 2·3 1·7 - 2·9 4738 84 1·8 1·4 - 2·2 
N = number at risk at baseline; n = incident cases; BCVA = best corrected visual acuity; 95% CI = 95% confidence interval. 
United States criteria· Incidence of moderate visual impairment: persons with baseline BCVA of 20/40 or better with follow-up BCVA worse than 20/40 but better than 20/200 (not including 20/40 or 20/200)· 
Incidence of blindness: persons with baseline BCVA better than 20/200 but follow-up BCVA 20/200 or worse (including 20/200). 
* P value < 0·05 
Age and sex standardized to the undivided Andhra Pradesh state population 
 
